Evidence Supporting Florastor (Saccharomyces boulardii) Efficacy
Florastor (Saccharomyces boulardii) is conditionally recommended for preventing C. difficile infection in adults and children receiving antibiotics, with the strongest evidence showing a 60% reduction in antibiotic-associated diarrhea risk, though it should NOT be used for treating active C. difficile infection. 1
Prevention of Antibiotic-Associated Diarrhea
The 2020 AGA Clinical Practice Guidelines provide a conditional recommendation with low-quality evidence for using S. boulardii in adults and children on antibiotic treatment to prevent C. difficile infection 1. The evidence base is substantial:
- Meta-analysis of 39 studies (9,955 patients) demonstrated that probiotics reduced overall C. difficile infection risk (RR 0.40; 95% CI 0.30-0.52), with benefits primarily in high-risk populations 1
- S. boulardii specifically reduced antibiotic-associated diarrhea from 18.7% to 8.5% (RR 0.47; 95% CI 0.38-0.57), with a number needed to treat of 10 2
- In children: reduced risk from 20.9% to 8.8% (RR 0.43; 95% CI 0.3-0.6) 2
- In adults: reduced risk from 17.4% to 8.2% (RR 0.49; 95% CI 0.38-0.63) 2
Recent real-world data from 2021 and 2023 support these findings:
- Hospital study of 8,763 patients showed 43% reduced risk of hospital-onset CDI when S. boulardii was co-administered with high-risk antibiotics (OR 0.57; 95% CI 0.33-0.96) 3
- Timing matters: Starting S. boulardii within 24 hours of antibiotic initiation showed 53% risk reduction (OR 0.47; 95% CI 0.23-0.97) 3
- Targeted use with ceftriaxone showed 76% risk reduction (aHR 0.24; 95% CI 0.11-0.53), with NNT of 100 4
Important Caveats
One large negative trial exists: A 2016 German multicenter RCT (477 patients) found no benefit for AAD prevention in hospitalized patients without specific risk factors (HR 1.02; 95% CI 0.55-1.90) 5. This contradicts the meta-analytic evidence but enrolled a lower-risk population in outpatient settings where baseline CDI risk is minimal.
Treatment of Active C. difficile Infection
The AGA makes NO recommendation for using probiotics to treat active C. difficile infection 1. The evidence is insufficient:
- Only 5 RCTs with 223 total patients evaluated S. boulardii as adjunctive treatment 6
- The largest study (124 patients) showed S. boulardii may increase diarrhea cessation (RR 1.33; 95% CI 1.02-1.74) and decrease recurrence (RR 0.59; 95% CI 0.35-0.98), but evidence quality was low 1, 6
- For recurrent CDI specifically: One 1994 trial showed benefit (recurrence 34.6% vs 64.7% placebo; P=0.04), but no benefit for initial episodes 7
- Data too heterogeneous to pool; high risk of bias across studies 6
Irritable Bowel Syndrome
Evidence for IBS-D is emerging but insufficient for guideline-level recommendations:
- A 2010 systematic review suggested S. boulardii "shows promise" for IBS treatment but recommended more supporting evidence 8
- A 2025 pediatric study (60 children) showed symptom improvement in IBS-D through gut microbiota modulation 9
- This evidence is too preliminary to make firm recommendations for IBS treatment
Clinical Algorithm for Use
Use S. boulardii for prevention when:
- Patient is starting high-risk antibiotics (fluoroquinolones, clindamycin, cephalosporins, broad-spectrum penicillins)
- Patient has high baseline CDI risk (hospitalized, elderly, recent antibiotic exposure, prior CDI)
- Start within 24 hours of antibiotic initiation for maximum benefit 3
- Continue for 7 days after antibiotic completion
- Dose: 250-500 mg twice daily
Do NOT use S. boulardii for:
- Treatment of active C. difficile infection (insufficient evidence; use standard antibiotics)
- Severely immunocompromised patients (risk of fungemia, though rare)
- Patients with central venous catheters who are critically ill (theoretical fungemia risk)
- Low-risk outpatients on short antibiotic courses (cost may outweigh minimal benefit)
Consider avoiding if:
- Patient places high value on cost avoidance and has low baseline CDI risk (outpatient setting) 1
- Patient is severely ill and values avoiding even theoretical harms 1
Safety Profile
S. boulardii is generally safe with no serious adverse events reported in major trials 8, 2, 7. The most common side effects are mild gastrointestinal symptoms. Rare cases of fungemia have been reported in severely immunocompromised patients, warranting caution in this population 10.